Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

Overview of attention for article published in Journal of Clinical Oncology, September 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news: 4 news outlets
blogs: 1 blog
twitter: 22 X users
reddit: 2 Redditors

video: 1 YouTube creator
guideline: 2 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 31 Mendeley

So far, Altmetric has seen 7 news stories from 4 outlets.

Selinexor, HER2-Targeting ADC May Provide Options for Endometrial Cancer

Cancer Network, 27 Aug 2026

CancerNetwork® spoke with Ritu Salani, MD, a board-certified gynecologic oncologist and director of gynecologic oncology at the…

SGO 2025: Impact of Precision Medicine in Endometrial Cancer

Medscape, 03 Apr 2025

Kathleen N. Moore, MD, discusses the need for individualized therapies, particularly for patients with nondeficient mismatch…

Episode 5: Immunotherapy and Advanced Endometrial Cancer

Medscape, 25 Sep 2024

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple…

Selinexor, HER2-Targeting ADC May Provide Options for Endometrial Cancer

Cancer Network, 18 Aug 2024

CancerNetwork® spoke with Ritu Salani, MD, a board-certified gynecologic oncologist and director of gynecologic oncology at the…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 3 additional news stories.